E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of small molecule drugs to treat genetically-defined subpopulations in neurodegenerative diseases. The Company focuses on genetically defined subpopulations that allow targeting therapies for patients where their disease is specifically driven by a genetic alteration. This approach provides greater confidence in the drug targets and allows to develop treatments for homogenous patient populations. E-Scape Bio's initial programs aim to improve the lives of both Alzheimer's Disease and Parkinson's Disease patients.